^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MCL1 expression

    i
    Entrez ID:
    4170
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL (NCT03319901)
    Phase 1/2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    10/30/2017
    Primary completion :
    04/30/2026
    Completion :
    04/30/2027
    BCL2
    |
    BCL2 expression • MCL1 expression
    |
    Venclexta (venetoclax)
    Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors (NCT02143401)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    11/07/2014
    Primary completion :
    11/30/2022
    Completion :
    05/20/2025
    MCL1 • AFP • CASP3
    |
    MCL1 expression
    |
    sorafenib • navitoclax (ABT 263)
    Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT05744739)
    Phase 1
    Northwestern University
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    09/29/2023
    Primary completion :
    04/23/2029
    Completion :
    04/23/2030
    MCL1
    |
    MCL1 expression
    |
    tomivosertib (eFT508)
    Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (NCT01303341)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    02/18/2011
    Primary completion :
    05/01/2012
    Completion :
    09/09/2024
    BCL2
    |
    BCL2 expression • MCL1 expression
    |
    sorafenib • riluzole
    Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies (NCT01188252)
    Phase 1
    Bayer
    Completed
    Last update posted :
    01/09/2017
    Initiation :
    08/01/2010
    Primary completion :
    06/01/2016
    Completion :
    12/01/2016
    CASP3 • CDKN1A • ANXA5
    |
    MCL1 expression
    |
    roniciclib (BAY1000394)